Numerous substances are available for the treatment of metastatic renal cell carcinoma (mRCC). Therefore, medical treatment of patients with mRCC has become a very complex subject. This review summarises clinical studies and typical side-effects of currently available agents that have been approved in Germany. The authors give suggestions for the use of these substances in the different therapy lines.
|Translated title of the contribution||Current recommendations for the systemic treatment of metastatic renal cell carcinoma|
|Number of pages||6|
|Publication status||Published - 04.09.2019|
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)